about
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients.Multiple hepatic abscesses due to Yersinia enterocolitica infection secondary to primary haemochromatosis.Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modellingNeurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinomaPopulation Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants.Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study.Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.A Cancer That Went Up in Smoke: Pulmonary Reaction to e-Cigarettes Imitating Metastatic Cancer.[Lactic acidosis in a 24-year-old woman with status asthmaticus].Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose.GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients.NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation.No evidence for taxane/platinum pharmacogenetic markers: just lack of power?Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients.Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--letter.Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients.Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancerLinkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populationsDuplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studiesResponse to Letter to the Editor concerning "Progression-free survival (PFS) in oncology: Caveat emptor!"A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24Progression-free survival in oncology: Caveat emptor!
P50
Q27852988-3622FAB8-838F-409B-A83B-499429C2BF50Q33665154-31519DFA-7C23-45EB-AB22-D5DF2D25A53FQ34331002-40AFC29A-91AF-4828-BA07-30E6C093FABDQ34571036-98F523D1-96AF-4513-A4AF-EE7873F6A869Q36802118-0A00E914-B2DF-4DE5-8F41-BCFBD60E40F1Q37700662-A6C32EBE-C56C-4135-A921-DF378616A9B3Q38726616-7233B451-B96A-4B97-9C02-A088008594E2Q38948699-1CD256A5-B229-458B-814C-CBEAE37BB00FQ39702921-C062DC4B-3AB1-49F5-A7DB-204D3E1A5D34Q40114459-7598EDB8-F9CA-4EBC-9A9E-5F07868FFE31Q40410653-EAB94085-B2A3-4827-8D73-277F240353F2Q40793437-A53B16D0-DCE2-42AC-A7E2-BE4B6F36E566Q43113975-4CCD6246-8876-4006-9DE1-C25E93BB7BFFQ43474093-0EE7A8E3-64A2-4C8A-A0AB-FB414F683964Q45344335-B6F8377B-1B7B-439F-BE7E-EDBE6B870FECQ46656669-520A90D2-1341-4882-AE23-0472A000AD14Q47956909-7E305735-9056-4064-954A-F5C29269EBD8Q50262932-23DFC9E3-7C4C-4D12-9672-3002588F0810Q50526560-30992F3B-D216-4696-8364-CCABCC84A016Q50557593-03B2A9C7-1292-4E98-B0F8-F17B61B7DDE8Q51157856-185B96AF-43DB-4FD2-B734-F09AFEDC5561Q51761715-053F6AB1-F574-46F6-A948-AADDAB0113DEQ57581249-3595B6D1-BFB9-4929-B962-A04F9D6EF867Q60705807-020C033C-6673-4861-9D77-650D87A55283Q60705860-A98D12CA-4FC5-4DB0-BADC-EEABAACEF177Q89184996-8D094DEB-5025-468C-9B65-8EB3145FA5F7Q91477784-B6D5161D-D09D-4913-BA85-B41F89A0B8D2Q92378452-B425580E-F3C5-4A43-AB7A-D408BB8BD72AQ92996366-7A92D99C-CA58-4306-8AB3-2BDB5A40F07E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Troels K Bergmann
@ast
Troels K Bergmann
@en
Troels K Bergmann
@es
Troels K Bergmann
@nl
Troels K Bergmann
@sl
type
label
Troels K Bergmann
@ast
Troels K Bergmann
@en
Troels K Bergmann
@es
Troels K Bergmann
@nl
Troels K Bergmann
@sl
prefLabel
Troels K Bergmann
@ast
Troels K Bergmann
@en
Troels K Bergmann
@es
Troels K Bergmann
@nl
Troels K Bergmann
@sl
P106
P31
P496
0000-0001-8313-0721